dronedarone has been researched along with Auricular Fibrillation in 286 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 51 (17.83) | 29.6817 |
| 2010's | 189 (66.08) | 24.3611 |
| 2020's | 46 (16.08) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Chu, H; Guo, X; Huang, L; Jia, J; Liu, L; Ma, X; Shan, J; Sun, H; Tang, Y; Wei, J; Xu, J; Yang, Q; You, Q; Zhang, X | 1 |
| Desai, NR; Everhart, A; Jena, A; Karaca-Mandic, P; Ross, JS; Shah, N; Smith, LB; Stecher, C | 1 |
| Boiron, R; Gandhi, SK; Reiffel, JA; Wieloch, M | 1 |
| Akoum, N; Bhatnagar, A; Dagher, L; El Hajjar, AH; Hua, H; Mansour, M; Marrouche, NF; Wazni, O | 1 |
| Abenhaim, L; Botto, GL; Breithardt, G; de Abajo, FJ; Grimaldi-Bensouda, L; Khachatryan, A; Kirchhof, P; Merino, JL; Stambler, B | 1 |
| Ma, CS; Sun, YH; Wu, SL | 1 |
| Calkins, H; Hohnloser, SH; Lip, GYH; Ludwigs, U; Nam, GB; Oldgren, J; Stewart, J; Ueng, KC; Vamos, M; Wieloch, M; Zhu, J | 1 |
| Atar, D; Crijns, HJGM; Kowey, P; Ludwigs, U; Pak, HN; Reiffel, J; Stewart, J; Thind, M; Wieloch, M; Zareba, W; Zhu, J | 1 |
| Kowey, PR; McKindley, DS; Naccarelli, GV; Reiffel, JA; Stewart, J; Thind, M | 1 |
| Cai, S; Liu, W; Pan, Y; Sun, P; Wang, M; Zhang, P; Zhao, Q | 1 |
| Huse, S; Koren, A; Piccini, JP; Ronk, CJ; Wharton, JM | 1 |
| Albuquerque, APA; Anker, SD; Braceras, R; Butler, J; Camm, AJ; Crijns, HJGM; Hohnloser, SH; Piccini, JP; Stewart, J; Vaduganathan, M; Wieloch, M | 1 |
| Boriani, G; Imberti, JF; Vitolo, M | 1 |
| Bigot, G; Bunch, TJ; Handelsman, Y; Konigsberg, L; Kowey, PR; Rodbard, HW; Steinberg, BA; Thind, M; Wieloch, M | 1 |
| Bai, R; Lin, JL; Ma, C; Nam, GB; Stewart, J; Sun, Y; Wieloch, M; Zhu, J | 1 |
| He, QF; Jiao, Z; Wen, HN; Xiang, XQ; Yu, JG | 1 |
| Peng, Y; Wang, P; Yan, D; Zhang, Z | 1 |
| Bunch, TJ; Kim, H; Lip, GYH; Reynolds, MR; Ronk, CJ; Steinberg, BA; Wieloch, M | 1 |
| Bigot, G; Blomström-Lundqvist, C; Hohnloser, SH; McKindley, DS; Naccarelli, GV; Wieloch, M | 1 |
| Charland, S; Faith, L; Ken-Opurum, J; Park, S; Preblick, R; Revel, A; Srinivas, SS; Vadagam, P | 1 |
| Chang, SH; Chen, SW; Huang, CH; Huang, YC; Huang, YT; Hung, KC; Kuo, CF; Tu, HT; Wang, CL; Wu, VC | 1 |
| Blomström-Lundqvist, C; Camm, AJ; Crotty, C; Fazeli, MS; Kowey, PR; Kreidieh, B; Singh, JP; Turakhia, MP | 1 |
| Blomström-Lundqvist, C; Camm, AJ; Din, N; Fan, J; Kabadi, S; Kowey, P; Pundi, K; Rashkin, J; Sandhu, AT; Singh, JP; Turakhia, MP; Wieloch, M | 1 |
| Deering, TF; Reiffel, JA; Solomon, AJ; Tamirisa, KP | 2 |
| Calkins, H; Corp Dit Genti, V; Hohnloser, SH; Koren, A; Kowey, PR; Torp-Pedersen, CT; Vamos, M; Wieloch, M | 1 |
| Packer, M | 1 |
| Dávid, Á; Körber, T; Wedler, K | 1 |
| Corp Dit Genti, V; Crijns, HJ; Koren, A; Kowey, PR; Naccarelli, GV; Reiffel, JA; Thind, M; Wieloch, M | 1 |
| Moore, Z; Nugent, L; O'Connor, T; Patton, D; Wilson, H | 1 |
| Desai, NR; Dowd, B; Everhart, A; Herrin, J; Higuera, L; Jeffery, MM; Jena, AB; Karaca-Mandic, P; Ross, JS; Shah, ND; Smith, LB | 1 |
| Li, F; Li, M; Li, Z; Luo, D; Qiao, J; Yu, F; Yu, Y; Zhang, J | 1 |
| Bhatt, DL; Camm, AJ; Le Heuzey, JY; Lombardi, F; Martinez, JM; Naccarelli, GV; Naditch-Brûlé, L; Tamargo, J | 1 |
| Maharshak, I; Paul, M; Steiner, H | 1 |
| Bohn, RL; Bozzi, S; Goehring, EL; Jones, JK; Naccarelli, GV; Pezzullo, J; Sicignano, N; Tamayo, RCSG; Tave, AK | 1 |
| Choi, EK; Kim, JA; Kim, JH; Kwon, TY; Lee, SR; Lee, YE; Oh, S | 1 |
| Blomström-Lundqvist, C; Connolly, S; Corp Dit Genti, V; Hohnloser, SH; Koren, A; Marrouche, N; Wieloch, M | 1 |
| Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ | 1 |
| Chan, ECY; Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Kambayashi, R; Matsumoto, A; Nunoi, Y; Sugiyama, A; Takei, Y; Venkatesan, G | 1 |
| Bohn, RL; Desai, V; Goehring, E; Jones, JK; Juhaeri, J; Sicignano, N; Tamayo, SG; Tave, A; Weiss, SR; Wu, C | 1 |
| Apicella, C; Fabritz, L; Fobian, D; Gupta, S; Holmes, AP; Kabir, SN; Kirchhof, P; Kuhlmann, SM; O'Reilly, M; O'Shea, C; Pavlovic, D; Reyat, JS; Saxena, P; Smith, GL; Syeda, F; Workman, AJ | 1 |
| Chan, ECY; Chin, SY; Tan, HL; Tang, LWT | 1 |
| Camm, AJ; Heijman, J; Hohnloser, SH | 1 |
| Boiron, R; Gandhi, S; Juhaeri, J; Kechemir, H; Lin, S; Wieloch, M; Wu, C | 1 |
| Boeken, U; Dalyanoĝlu, H; Lichtenberg, A; Makimoto, H; Sipahi, FN; Sugimura, Y; Yilmaz, E | 1 |
| Bhattacharyya, N; Bogard, A; Curtis, AB; Hohnloser, SH; Malik, A; Stewart, J; Zeitler, EP | 1 |
| Hamlin, RL; Kijtawornrat, A; Limprasutr, V; Saengklub, N; Sawangkoon, S | 1 |
| Cars, T; Lindhagen, L; Malmström, RE; Neovius, M; Schwieler, J; Sundström, J; Wettermark, B | 1 |
| Aronow, WS; Khan, MH; Rochlani, Y | 1 |
| Ando, K; Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Lubna, NJ; Motokawa, Y; Naito, AT; Nakamura, Y; Sugiyama, A; Yamazaki, H | 1 |
| Delgado-Baeza, E; Delgado-Martos, MJ; Desco, M; Gomez de Diego, JJ; Muñoz-Valverde, D; Quintana-Villamandos, B; Soto-Montenegro, ML | 1 |
| Dai, W; Gandhi, S; Juhaeri, J; Kechemir, H; Lin, S; Tcherny-Lessenot, S; Wang, Y; Wu, C | 1 |
| Friberg, L | 3 |
| Ehrlich, JR | 1 |
| Ariano, C; De Vecchis, R | 1 |
| Ehrlich, JR; Goette, A; Israel, CW; Kostev, K; Look, C | 1 |
| Babu Dasari, J; Battaini, F; Bernardini, S; De Lorenzo, A; Intorcia, A; Merra, G; Morgagni, R; Perrone, MA; Romeo, F; Sergi, D | 1 |
| Reiffel, JA | 3 |
| Chang, KC; Chen, CP; Chen, MC; Chen, SA; Cheng, CW; Feng, AN; Hsieh, MH; Hsu, JC; Ko, WC; Kuo, JY; Lai, WT; Lin, JL; Liu, JC; Lu, YY; Shyu, KG; Tseng, WK; Ueng, KC; Wen, MS; Wu, TJ; Yang, TY; Yeh, KH | 1 |
| Bergfeldt, L; Blomström-Lundqvist, C; Boriani, G; Botto, GL; Camm, AJ; Capucci, A; Goette, A; Hohnloser, SH; Israel, CW; Lozano, IF; Merino, JL | 1 |
| Blomström-Lundqvist, C; Dagres, N; Lewalter, T; Lip, GY; Pison, L; Proclemer, A | 1 |
| Berg, J; Connolly, S; Lindgren, P; Sauriol, L | 1 |
| Camm, AJ; Savelieva, I | 2 |
| Breithardt, G; Eckardt, L; Frommeyer, G; Kaese, S; Kaiser, D; Milberg, P; Uphaus, T | 1 |
| Braun-Dullaeus, RC; Esperer, HD; Genz, C; Kluba, K; Rauwolf, T; Said, SM; Schmeisser, A | 1 |
| Cinnamond, N; Connolly, M; Damani, L; Hussey, S; Menown, IB | 1 |
| Jahn, S; Lackner, C; Stauber, RE; Zollner, G | 1 |
| Gonzalez, JE; Krantz, MJ; Sauer, WH | 1 |
| Belardinelli, L; Kanas, AF; Machado, AD; Nearing, BD; Pagotto, VP; Sobrado, LF; Sobrado, MF; Varone, BB; Verrier, RL; Zeng, D | 1 |
| Morley, GE; Park, DS | 1 |
| Elpern, DJ; Ladizinski, B | 1 |
| Connolly, SJ; Crijns, HJ; Hohnloser, SH; Naditch-Brûlé, L; Page, RL; Pisters, R; Torp-Pedersen, C | 1 |
| Boriani, G; Botto, GL; Brignole, M; Calò, L; Calvi, V; Capucci, A; De Ponti, R; De Simone, A; Delise, P; Di Biase, M; Lombardi, F; Lunati, M; Raviele, A; Santomauro, M; Senni, M; Stabile, G; Themistoclakis, S; Tritto, M; Volpe, M | 1 |
| Chen, SA; Chen, YJ; Hsieh, MH; Huang, JH; Lin, YK | 1 |
| Goldberger, JJ; Teme, T | 1 |
| Naccarelli, GV | 2 |
| Caubel, P; Dai, W; Juhaeri, J; Koren, A; Tcherny-Lessenot, S; Thammakhoune, J; Wu, C; Wu, J | 1 |
| Ravens, U | 1 |
| Clarke, S; Flego, G; Haupt, E; Iannone, P; Magrini, N; Minardi, M; Truglio, P | 1 |
| Jhaveri, M; Kim, MH; Koren, A; Lin, J | 1 |
| Hohnloser, SH | 2 |
| Connolly, SJ; Halperin, JL; Hohnloser, SH; John Camm, A; Radzik, D | 1 |
| Kim, J; Lee, EJ | 1 |
| Kowey, PR; Naccarelli, GV | 1 |
| Byeon, K; Chun, KJ; Im, SI; Kim, JS; On, YK; Park, KM; Park, SJ | 1 |
| Bianco, D; Bizzarri, N; Brunelli, C; Ferrero, S; Parodi, A; Rosa, GM; Valbusa, A; Zawaideh, C | 1 |
| Barthel, P; Dössel, O; Loewe, A; Lutz, Y; Schmidt, G; Scholz, EP; Seemann, G; Sinnecker, D; Wilhelms, M | 1 |
| Camm, AJ; Connolly, SJ; Gao, P; Halperin, JL; Hohnloser, SH; Radzik, D | 1 |
| Aliot, EM; Capucci, A; Connolly, S; Crijns, HJ; Guerra, F; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D | 1 |
| Al-Khatib, SM; Allen LaPointe, NM; Dai, D; Peterson, ED; Piccini, JP; Thomas, L | 1 |
| Figulla, HR; Franz, M; Gecks, T; Jung, C; Kühnert, H; Prochnau, D; Schliemann, S | 1 |
| Boddy, A; DiMarco, JP; Ellenbogen, KA; Ezekowitz, MD; Geba, GP; Kaszala, K; Koren, A; P, GG | 1 |
| Benninger, G; Bosch, RF; Goette, A; Paar, WD; Pittrow, D; von Stritzky, B | 1 |
| Bajer, M; Braun-Dullaeus, RC; Esperer, HD; Hahn, J; Said, SM | 1 |
| Aguilar, C | 1 |
| Juhlin, T; Mochalina, N; Platonov, PG; Svensson, PJ; Wieloch, M | 1 |
| Ahuja, N; Casto, A; Nguyen, DV; Stack, S | 1 |
| Belardinelli, L; Camm, AJ; Karwatowska-Prokopczuk, E; Kowey, P; Olmsted, A; Reiffel, JA; Rosero, S; Zareba, W; Zeng, D | 1 |
| Adelstein, E; Alam, MB; Jain, SK; Khattak, F; Leef, G; Munir, MB; Patel, D; Qin, D; Rattan, R; Saba, S | 1 |
| Capucci, A; Guerra, F; Matassini, MV; Scappini, L; Urbinati, A | 1 |
| Hohnloser, SH; Vamos, M | 1 |
| Andrade, JG; Nattel, S; Tadros, R | 1 |
| Ahsan, SY; Di Mario, C; Hayward, C; Lyon, AR; Patel, HC; Patel, K; Rowland, E | 1 |
| Ehrlich, JR; Kaess, BM | 1 |
| Arceluz, M; Escobar, C; López-Sendón, JL; Merino, JL; Montes de Oca, R; Mori, R | 1 |
| Biffi, M; Boriani, G; Diemberger, I; Lorenzetti, S; Martignani, C; Massaro, G; Reggiani, MLB; Ziacchi, M | 1 |
| Nguyen, E; White, CM | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Cullington, D | 1 |
| Kowey, PR; Laughlin, JC | 1 |
| Alings, A; Davy, JM; Herold, M; Hoglund, C; Radzik, D; Timmermans, A; Van Kempen, L | 1 |
| Preobrazhenskiĭ, DV | 2 |
| Conway, E; Kowey, PR; Musco, S | 1 |
| Kułakowski, P | 1 |
| Ehrlich, JR; Nattel, S | 1 |
| Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M | 4 |
| Verma, A | 1 |
| Zimetbaum, PJ | 1 |
| Krishnamoorthy, S; Lip, GY | 1 |
| Tejani, AM; Yih, V | 1 |
| Horner, SM | 1 |
| Floyd, J | 1 |
| Costantino, G; Podda, GM; Pugliano, M | 1 |
| Brachmann, J; Sinha, AM | 1 |
| Tandogan, I; Turgut, OO; Yalta, K; Yilmaz, A; Yilmaz, MB | 1 |
| Kowey, PR; Patel, C; Yan, GX | 1 |
| Arora, BL; Arora, RR; Bhuriya, R; Patel, DD; Patel, PD; Singh, PP | 1 |
| Califf, RM; Hasselblad, V; Kong, DF; Peterson, ED; Piccini, JP; Washam, JB | 1 |
| Chan, PS; Nallamothu, BK; Oral, H | 1 |
| Camm, AJ; Falk, RH | 1 |
| Hamad, B; Kirkpatrick, P; Page, RL | 1 |
| Duray, GZ; Ehrlich, JR; Hohnloser, SH | 1 |
| Christiansen, CB; Køber, L; Torp-Pedersen, C | 2 |
| Garg, RK; Hundal, M | 1 |
| Prystowsky, EN | 1 |
| Gleason, PP; Kjesbo, NK; Schafer, JA | 1 |
| Cook, GE; Sasich, LD; Sukkari, SR | 2 |
| Lewalter, T | 2 |
| Cooper, JA | 1 |
| Clem, JR; Farver, DK; Fischer, JR; Johnson, TJ | 1 |
| Goette, A | 1 |
| Brachmann, J; Duray, G; Goette, A; Hohnloser, SH; Lewalter, T; Pittrow, D; Schmitt, J | 1 |
| Goette, A; Hohnloser, S; Kirch, W; Lewalter, T; Pittrow, D | 1 |
| Laufs, U; Röther, J | 1 |
| Dobrev, D; Nattel, S | 1 |
| Cingolani, E; Diamond, GA; Kaul, S; Singh, D | 1 |
| Davy, JM; De Ferrari, GM; Le Heuzey, JY; Radzik, D; Santini, M; Zhu, J | 1 |
| Rosei, EA; Salvetti, M | 1 |
| Sahadevan, J; Waldo, AL | 1 |
| Duray, GZ; Hohnloser, SH; Schmitt, J | 1 |
| Dorian, P | 1 |
| Antzelevitch, C; Belardinelli, L; Burashnikov, A | 1 |
| Johnston, SS; Lin, J; Naccarelli, GV; Patel, PP; Schulman, KL | 1 |
| Baroletti, S; Catella, J; Cheng, JW; Ehle, M | 1 |
| Franz, MR; Singh, SN | 1 |
| Coons, JC; Plauger, KM; Seybert, AL; Sokos, GG | 1 |
| Crijns, H; Röther, J | 1 |
| Banchs, J; Gonzalez, M; Naccarelli, G; Penny-Peterson, E; Samii, S; Wolbrette, D | 1 |
| Clem, JR | 1 |
| Hilleman, DE; Mooss, AN | 1 |
| Cohenour, FV; Freeman, MK; Hughes, PJ; Price, EM | 1 |
| Antzelevitch, C; Belardinelli, L; Burashnikov, A; Di Diego, JM; Sicouri, S | 1 |
| Connolly, SJ; Hohnloser, SH | 1 |
| Becker, RC; Fiuzat, M; Shirolkar, SC | 1 |
| Gil Núñez, A | 1 |
| Duray, GZ; Fink, A; Hohnloser, SH | 1 |
| Fox, D; Maund, E; McKenna, C; Palmer, S; Pepper, C; Sarowar, M; Stevenson, M; Woolacott, N | 2 |
| Lip, GY; Pamukcu, B | 2 |
| Huikuri, HV; Raatikainen, MJ | 1 |
| Naccarelli, GV; Singh, BN | 1 |
| Cingolani, E; Singh, BN | 1 |
| Singh, BN | 1 |
| Banchs, JE; Gonzalez, MD; Naccarelli, GV; Penny-Peterson, E; Samii, S; Wolbrette, DL | 2 |
| Gonska, BD | 1 |
| Brachmann, J; Ritscher, G; Simon Demel, K; Simon, H; Turschner, O | 1 |
| Sulimov, VA | 1 |
| Abdollah, H; Baranchuk, AM; Michael, KA; Miranda, RI; Redfearn, DP; Simpson, CS | 1 |
| Burkhardt, JD; Di Biase, L; Natale, A; Pelargonio, G; Santangeli, P | 1 |
| Albert, N; Anderson, JL; Buller, CE; Cannom, DS; Creager, MA; Crijns, HJ; Curtis, AB; Ellenbogen, KA; Estes, NA; Ettinger, SM; Ezekowitz, MD; Fuster, V; Guyton, RA; Halperin, JL; Hochman, JS; Jackman, WM; Jacobs, AK; January, CT; Kay, GN; Kushner, FG; Le Heuzey, JY; Lowe, JE; Ohman, EM; Olsson, S; Page, RL; Prystowsky, EN; Rydén, LE; Slotwiner, DJ; Stevenson, WG; Tamargo, JL; Tarkington, LG; Tracy, CM; Wann, LS; Yancy, CW | 1 |
| Eckert, L; Freemantle, N; Lafuente-Lafuente, C; Mitchell, S; Reynolds, M | 1 |
| Saliba, W; Wazni, OM | 1 |
| Becker, R; Katus, HA; Schweizer, PA; Thomas, D | 1 |
| Connolly, SJ; Duray, GZ; Hohnloser, SH; Torp-Pedersen, C | 1 |
| Capucci, A; Marinelli, A | 1 |
| Deshmukh, AJ; Karam, P; Mehta, J; Paydak, H; Singla, S | 1 |
| Kong, DF; Piccini, JP | 1 |
| Burke, JF; Mohmand-Borkowski, A; Penugonda, N | 1 |
| Brenner, R; Delacrétaz, E | 1 |
| Bushardt, RL; Jones, KW | 1 |
| Lunati, M; Pedretti, S | 1 |
| Caballero, R; Delpón, E; López-Farré, A; Tamargo, J | 1 |
| Russo, AM | 1 |
| Broncel, M; Dorantowicz, R | 1 |
| Dobrev, D | 1 |
| Mélon, P | 1 |
| Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C | 1 |
| Khanna, V; Reynolds, M; Reynolds, MR; Rutzen-Lopez, H; Vkhanna, V | 1 |
| Le Heuzey, JY | 1 |
| Lombardi, F; Marzocchi, M | 1 |
| Arnaout, M; Beuzeboc, P; Lokiec, F; Moachon, L; Mongardon, N; Pène, F; Rezai, K; Vodovar, D | 1 |
| Aikens, TH; Ezekowitz, MD; Nagarakanti, R; Shapiro, T | 1 |
| Calkins, H; Lim, SH; Sinha, SK | 1 |
| Banach, M; Budrejko, S; Kozlowski, D; Lip, GY; Mikhailidis, DP; Raczak, G; Rysz, J | 1 |
| Büchler, P; Estner, H; Huber, W; Joghetaei, N; Weirich, G | 1 |
| Dai, WS; Gao, S; Juhaeri, J; Koren, AT; Schiappacasse, HA | 1 |
| Nattel, S | 1 |
| Afzal, R; Alings, M; Amerena, J; Atar, D; Avezum, Á; Baret-Cormel, L; Blomström, P; Borggrefe, M; Budaj, A; Camm, AJ; Chen, SA; Ching, CK; Chrolavicius, S; Commerford, P; Connolly, SJ; Dans, A; Davy, JM; Delacrétaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Halperin, JL; Heidbüchel, H; Hohnloser, SH; Joyner, C; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Staiger, C; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsányi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Weinling, E; Xavier, D; Yusuf, S; Zhu, J; Zhu, JR | 1 |
| Aderkast, C; Bochmann, S; Bramlage, P; Bukowska, A; Chilukoti, RK; Goette, A; Hammwöhner, M; Lendeckel, U; Mostertz, J; Röhl, FW; Schild, L; Sixdorf, A; Wiswedel, I; Wolke, C | 1 |
| Lip, GY; Shantsila, A | 2 |
| Anastasiou-Nana, M; Dagres, N; Iliodromitis, EK; Lekakis, JP; Rallidis, LS; Varounis, C | 1 |
| Boiangiu, C; Cohen, M | 1 |
| Bruno, OD; Rizzo, LF | 1 |
| Fischer, GW; Trigo, P | 1 |
| Overbeck, P | 2 |
| Mullard, A | 1 |
| Blandino, A; Disertori, M; Gaita, F; Toso, E | 1 |
| Antenucci, C; Antonicelli, R; Bocconcelli, P; Boriani, G; Busacca, P; Capucci, A; Ciampani, N; Della Casa, S; Gabrielli, D; Galvani, M; Guerra, F; Margheri, M; Melandri, F; Modena, MG; Perna, GP; Pieri, P; Piovaccari, G; Pozzolini, A; Rapezzi, C; Villani, GQ | 1 |
| De Ponti, F; Mugelli, A | 1 |
| Åkerborg, Ö; Bégo-Le Bagousse, G; Lindgren, P; Nilsson, J; Rosenquist, M | 1 |
| Aikat, S; Chatterjee, S; Ghosh, J; Lichstein, E; Mukherjee, D | 1 |
| Åkerborg, Ö; Bascle, S; Lindgren, P; Nilsson, J; Reynolds, M | 1 |
| Boenigk, H; Braun-Dullaeus, RC; Esperer, HD; Genz, C; Herold, J; Kluba, K; Said, SM; Schmeisser, A; Wiedemann, AK | 1 |
| Becker, R; Katus, HA; Schmidt, C; Schweizer, PA; Thomas, D; Wiedmann, F | 1 |
| Avila Martínez, RJ; Benavides Mañas, PD; Catalán, JS; Díaz de Atauri Rodríguez, MJ; Hernández Voth, AR; Peñalver Paolini, CL | 1 |
| Hoffmeister, P; Peralta, A; Reynolds, M; Rosman, J | 1 |
| Duncker, D; Gardiwal, A; Klein, G; König, T; Lüsebrink, U; Oswald, H; Schreyer, H | 1 |
| Lindsay, BD | 1 |
| Ahmad, Y; Lip, GY | 1 |
| Saklani, P; Skanes, A | 1 |
| De Ferrari, GM; Dusi, V | 1 |
| Belardinelli, L; Kanas, AF; Nearing, BD; Pagotto, VP; Sobrado, MF; Verrier, RL; Zeng, D | 1 |
| Botto, GL; Campana, C; Mariconti, B; Pentimalli, F; Russo, G | 1 |
| Bai, R; Lin, L | 1 |
| Bollmann, A; Hindricks, G; Husser, D; John, S; Kornej, J; Löbe, S; Salmas, J; Sörnmo, L; Stridh, M | 1 |
| Adamski, H; Chevrant-Breton, J; Dupuy, A; Le Gall, F; Miquel, J; Oger, E; Pollard, E | 1 |
| Salam, AM | 1 |
| Adlan, AM; Lip, GY | 1 |
| Aliot, E; Capucci, A; Connolly, S; Crijns, H; Hohnloser, S; Immordino, L; Kowey, P; Radzik, D; Roy, D | 1 |
| Singh, S | 1 |
| Cheng, TO | 1 |
| Karle, CA; Kathofer, S; Thomas, D | 1 |
| Zareba, KM | 1 |
| Klein, HH | 1 |
| Ehrlich, JR; Hohnloser, SH; Wegener, FT | 1 |
| Schwender, T | 1 |
| Le Grand, B; Sablayrolles, S | 1 |
| Coceani, M | 1 |
| Dale, KM; White, CM | 1 |
| Rowles, J; Tafreshi, MJ | 1 |
| Aliot, EM; Capucci, A; Connolly, SJ; Crijns, HJ; Hohnloser, SH; Kowey, PR; Radzik, D; Roy, D; Singh, BN | 1 |
| Ezekowitz, MD | 1 |
| Cannon, CP; Morrow, JP; Reiffel, JA | 1 |
| Connolly, SJ; Crijns, HJ; Hohnloser, SH; Page, RL; Seiz, W; Torp-Petersen, C | 1 |
| Arlet, JB; Capron, L; Chouchana, L | 1 |
| Kayser, SR | 1 |
| Fink, AH | 1 |
| White, CM | 1 |
| Gautier, P; Guillemare, E; Marion, A; Nisato, D | 1 |
| Bianconi, L; Castro, A; Santini, M | 1 |
90 review(s) available for dronedarone and Auricular Fibrillation
| Article | Year |
|---|---|
Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Network Meta-Analysis; Sotalol | 2023 |
Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Flecainide; Humans | 2021 |
Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Humans | 2021 |
Efficacy and safety of dronedarone in the treatment of patients with atrial fibrillation.
Topics: Age Factors; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Patient Selection; Randomized Controlled Trials as Topic; Risk Factors | 2017 |
Effects of dronedarone on all-cause mortality and on cardiovascular events in patients treated for atrial fibrillation: a meta-analysis of RCTs.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Dronedarone; Heart Failure; Humans; Randomized Controlled Trials as Topic; Secondary Prevention; Time Factors | 2019 |
Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Dabigatran; Digoxin; Dronedarone; Drug Interactions; Factor Xa Inhibitors; Heart Failure; Hospitalization; Humans; Mortality; Pyridines; Randomized Controlled Trials as Topic; Thiazoles | 2019 |
[New developments in the antiarrhythmic therapy of atrial fibrillation].
Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Piperazines; Pyrrolidines; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2014 |
An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Failure; Hospitalization; Humans; Proportional Hazards Models; Risk Factors; Treatment Outcome | 2014 |
The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Half-Life; Heart Failure; Hospitalization; Humans; Randomized Controlled Trials as Topic; Risk; Secondary Prevention | 2014 |
Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cost-Benefit Analysis; Dronedarone; Drug Costs; Humans; Risk Assessment; Treatment Outcome | 2014 |
Antithrombotic therapy in a patient with mild haemophilia A and atrial fibrillation: case report and brief review of the literature.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Aspirin; Atrial Fibrillation; Disease Management; Dronedarone; Fibrinolytic Agents; Hemophilia A; Hemorrhage; Humans; Male; Thrombophilia | 2015 |
New anthyarrhythmic drugs for atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Pyrrolidines; Ranolazine | 2015 |
Amiodarone and dronedarone: An update.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dronedarone; Drug Interactions; Heart Conduction System; Heart Rate; Humans; Patient Selection; Risk Factors; Treatment Outcome | 2016 |
Dronedarone: Basic Pharmacology and Clinical Use.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2016 |
Outcomes with Dronedarone in Atrial Fibrillation: What Differences Between Real-World Practice and Trials? A Meta-Analysis and Meta-Regression Analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Randomized Controlled Trials as Topic; Regression Analysis | 2017 |
Novel Use of Ranolazine as an Antiarrhythmic Agent in Atrial Fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Clinical Trials as Topic; Dronedarone; Drug Therapy, Combination; Humans; Male; Ranolazine; Recurrence; Treatment Outcome | 2017 |
Dronedarone: a new treatment for atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dronedarone; Humans | 2008 |
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?
Topics: Amiodarone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazolidines; Piperazines; Pyrrolidines | 2008 |
Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Humans; Pyrrolidines | 2009 |
Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Humans | 2009 |
[Dronedarone: the new antiarrythmic agent?].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Conduction System; Heart Rate; Humans; Models, Cardiovascular | 2009 |
Dronedarone: a promising alternative for the management of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Interactions; Heart Rate; Humans; Randomized Controlled Trials as Topic | 2009 |
Dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans; Ion Channels; Kaplan-Meier Estimate | 2009 |
Dronedarone for atrial fibrillation: a new therapeutic agent.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Evidence-Based Medicine; Heart Rate; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Heart Rate; Humans; Randomized Controlled Trials as Topic; Sinoatrial Node; Treatment Outcome | 2009 |
Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation.
Topics: Adrenergic Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Ion Channels; Randomized Controlled Trials as Topic; Vasodilator Agents | 2010 |
Efficacy and safety of dronedarone: a review of randomized trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Heart Failure; Heart Rate; Humans; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2010 |
Dronedarone--a new alternative for management of atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Heart Failure; Heart Rate; Humans; Patents as Topic; Secondary Prevention | 2010 |
Dronedarone: current evidence and future questions.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dronedarone; Drug Interactions; Evidence-Based Medicine; Humans; Patient Selection; Risk Assessment; Treatment Outcome | 2010 |
Dronedarone: a safety comparison to amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Creatinine; Dronedarone; Drug Approval; Drug Interactions; Drug Monitoring; Humans; United States; United States Food and Drug Administration | 2010 |
[Current antiarrhythmic drug therapy in atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2010 |
[Clinical profile of the new antiarrhythmic drug dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Drug Administration Schedule; Electrocardiography; Humans; Kaplan-Meier Estimate; Randomized Controlled Trials as Topic; Stroke | 2010 |
[Clinical pharmacology and electrophysiological properties of dronedarone].
Topics: Adrenergic Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; Calcium Channels; Disease Models, Animal; Dronedarone; Electrocardiography; Half-Life; Humans; Metabolic Clearance Rate; Sodium Channels | 2010 |
[Preventing stroke by treating atrial fibrillation--new hope with dronedarone and dabigatran?].
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dronedarone; Drug Therapy, Combination; Humans; Pyridines; Risk Factors; Stroke; Survival Rate; Thrombin; Vitamin K | 2010 |
New antiarrhythmic drugs for treatment of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Atrial Fibrillation; Dronedarone; Humans; Piperazines; Pyrrolidines; Ranolazine; Renin-Angiotensin System | 2010 |
Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?
Topics: Amiodarone; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Practice Guidelines as Topic; Treatment Outcome | 2010 |
Impact of dronedarone in atrial fibrillation and flutter on stroke reduction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Humans; Stroke | 2010 |
Dronedarone: an emerging therapy for atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Approval; Heart Rate; Heart Ventricles; Humans; Secondary Prevention; Treatment Outcome | 2010 |
Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dronedarone; Fibrinolytic Agents; Humans; Pyridines; Risk Factors; Stroke | 2010 |
Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Contraindications; Dronedarone; Drug Approval; Humans; Product Surveillance, Postmarketing; Stroke Volume | 2010 |
Dronedarone: an alternative to amiodarone?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Dronedarone; Drug Interactions; Humans | 2010 |
Dronedarone and vitamin K antagonists: a review of drug-drug interactions.
Topics: Amiodarone; Anticoagulants; Atrial Fibrillation; Dronedarone; Drug Interactions; Drug Therapy, Combination; Humans; Vitamin K; Warfarin | 2010 |
Dronedarone for the treatment of atrial fibrillation and atrial flutter.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dronedarone; Humans; Middle Aged; Randomized Controlled Trials as Topic | 2010 |
Dronedarone for atrial fibrillation?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
A new agent for atrial fibrillation: electrophysiological properties of dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dronedarone; Electrophysiologic Techniques, Cardiac; Humans | 2010 |
A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Controlled Clinical Trials as Topic; Dronedarone; Heart Failure; Humans; Risk Factors; Secondary Prevention | 2010 |
[Dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; Catheter Ablation; Combined Modality Therapy; Dose-Response Relationship, Drug; Dronedarone; Electrocardiography; Humans; Practice Guidelines as Topic; Premedication; Randomized Controlled Trials as Topic | 2010 |
[New developments in the antiarrhythmic therapy of atrial fibrillation].
Topics: Acetanilides; Aged; Amiodarone; Animals; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Electrocardiography; Heart Atria; Heart Failure; Heart Ventricles; Humans; Piperazines; Potassium Channels; Pyrrolidines; Ranolazine; Sodium Channels; Stroke | 2010 |
[Novel targets in the treatment of patients with atrial fibrillation: from elimination of symptoms to improvement of clinical outcomes].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Clinical Trials as Topic; Dronedarone; Electrocardiography; Heart Rate; Hospitalization; Humans; Monitoring, Physiologic; Practice Patterns, Physicians'; Secondary Prevention; Thromboembolism; Treatment Outcome | 2010 |
Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Disease Models, Animal; Dronedarone; Female; Heart Rate; Humans; Male | 2011 |
Advances in the treatment of atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Dronedarone; Drug Therapy, Combination; Heart Conduction System; Humans; Pyrrolidines; Treatment Outcome | 2010 |
The pharmaceutical pipeline for atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Antioxidants; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrrolidines; Renin-Angiotensin System; Treatment Outcome | 2011 |
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Flecainide; Humans; Male; Middle Aged; Propafenone; Randomized Controlled Trials as Topic; Sotalol; Treatment Outcome | 2011 |
Sinus rhythm restoration and treatment success: insight from recent clinical trials.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Clinical Trials as Topic; Dronedarone; Electric Countershock; Evidence-Based Medicine; Female; Heart Conduction System; Heart Rate; Humans; Male; Recurrence; Treatment Outcome | 2011 |
Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Failure; Hospitalization; Humans | 2011 |
Antiarrhythmic drugs for atrial fibrillation.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Pyrrolidines; Stroke; Treatment Outcome | 2011 |
Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Heart Rate; Humans; Sinoatrial Node | 2012 |
Dronedarone for the management of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Humans; Treatment Outcome | 2011 |
Dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Dronedarone; Drug Interactions; Heart Rate; Humans; Recurrence; Treatment Outcome | 2011 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Finland; Humans; Patient Selection; Practice Guidelines as Topic; Pyrrolidines | 2011 |
[The role of dronedarone in the contemporary atrial fibrillation treatment].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2011 |
Atrial fibrillation: epidemiology, prognosis and therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Dronedarone; Electric Countershock; Heart Rate; Humans; Prognosis; Quality of Life; Risk Factors; Thromboembolism | 2011 |
Dronedarone for atrial fibrillation therapy.
Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Half-Life; Heart Rate; Humans; Time Factors | 2011 |
Update on the management of atrial fibrillation: anticoagulation and medical therapy.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Dronedarone; Drug Approval; Evidence-Based Medicine; Factor Xa Inhibitors; Female; Humans; Infusions, Intravenous; Male; Practice Guidelines as Topic; Pyridines; Pyrrolidines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2011 |
Dronedarone: an overview.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Dronedarone; Heart Rate; Hospitalization; Humans; Treatment Outcome | 2012 |
Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Cost-Benefit Analysis; Dronedarone; Drug Costs; Humans; Quality-Adjusted Life Years; Technology Assessment, Biomedical; United Kingdom | 2012 |
Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Incidence; Ischemic Attack, Transient; Models, Statistical; Randomized Controlled Trials as Topic; Stroke | 2011 |
The management of patients with atrial fibrillation and dronedarone's place in therapy.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dronedarone; Heart Rate; Humans; Practice Guidelines as Topic; Risk Factors; Sex Factors | 2011 |
[Amiodarone and thyroid dysfunction].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Hypothyroidism; Iodine; Thyroid Gland; Thyrotoxicosis | 2012 |
Managing atrial fibrillation in the elderly: critical appraisal of dronedarone.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Female; Heart Failure; Humans; Liver; Male; Multicenter Studies as Topic | 2012 |
[Dronedarone: a real innovation or a mere second-best choice? How to find the way among guidelines, regulatory agencies and daily clinical practice].
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Liver Failure, Acute; Liver Function Tests; Practice Guidelines as Topic | 2012 |
Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Failure; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Atrial fibrillation: new drugs, devices, and procedures.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dronedarone; Equipment and Supplies; Humans; Warfarin | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Novel anti-arrhythmic medications in the treatment of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Digoxin; Dronedarone; Forecasting; Heart Failure; Humans; Phenethylamines; Piperazines; Pyrrolidines; Ranolazine; Sulfonamides; Technology, Pharmaceutical; Ventricular Dysfunction, Left | 2012 |
Drug safety evaluation of dronedarone in atrial fibrillation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Labeling; Hospitalization; Humans; Patient Selection; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2012 |
Dronedarone in atrial fibrillation: the aftermath of the PALLAS trial.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Dronedarone; Drug Monitoring; Early Termination of Clinical Trials; Humans; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Heart Failure; Heart Rate; Humans; Risk Assessment | 2013 |
Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Indoles; Oxazines; Phenethylamines; Piperazines; Serotonin 5-HT4 Receptor Antagonists; Sulfonamides | 2004 |
The novel antiarrhythmic drug dronedarone: comparison with amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans; Ion Channels | 2005 |
[Dronedarone--a new therapeutic option for controlling atrial rhythm and ventricular frequency].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Atrial Fibrillation; Atrial Function; Creatinine; Dose-Response Relationship, Drug; Dronedarone; Electrophysiology; Humans; Secondary Prevention; Ventricular Function | 2006 |
Dronedarone: an emerging agent with rhythm- and rate-controlling effects.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Forecasting; Heart Rate; Humans; Practice Patterns, Physicians'; Treatment Outcome | 2006 |
Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dronedarone; Humans | 2006 |
Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Biological Availability; Clinical Trials as Topic; Dronedarone; Drug Interactions; Half-Life; Humans | 2007 |
Dronedarone: drondarone, SR 33589, SR 33589B.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Drug Interactions; Humans; Potassium Channel Blockers | 2007 |
A review of the investigational antiarrhythmic agent dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Drugs, Investigational; Humans; Ion Channels; Membrane Potentials; Molecular Structure | 2007 |
New antiarrhythmic treatment of atrial fibrillation.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzofurans; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Carbazoles; Carvedilol; Cyclopropanes; Dronedarone; Fatty Acids, Omega-3; Furans; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oligopeptides; Organic Chemicals; Peptidyl-Dipeptidase A; Potassium Channel Blockers; Propanolamines; Purinergic P1 Receptor Agonists | 2007 |
New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Evaluation; Heart Rate; Humans; Sinoatrial Node; Treatment Outcome | 2007 |
Dronedarone: in quest of the ideal antiarrhythmic drug.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; Clinical Trials, Phase III as Topic; Dronedarone; Drug Interactions; Electrophysiology; Humans; Safety; Treatment Outcome | 2007 |
New antiarrhythmic drugs for the treatment of atrial fibrillation.
Topics: Aminobenzoates; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sotalol; Sulfonamides | 2002 |
29 trial(s) available for dronedarone and Auricular Fibrillation
| Article | Year |
|---|---|
Effect of DrOnedarone on atrial fibrosis progression and atrial fibrillation recurrence postablation: Design of the EDORA randomized clinical trial.
Topics: Atrial Fibrillation; Catheter Ablation; Contrast Media; Dronedarone; Fibrosis; Gadolinium; Heart Atria; Humans; Prospective Studies; Quality of Life; Recurrence; Treatment Outcome | 2021 |
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial.
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Humans; Kidney; Renal Insufficiency, Chronic | 2022 |
Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans; Kidney; Treatment Outcome | 2022 |
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.
Topics: Adonis; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Diabetes Mellitus; Dronedarone; Humans | 2022 |
Effect of Dronedarone in the Treatment of Atrial Fibrillation in the Asian Population: Post Hoc Analysis of the ATHENA Trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Humans; Treatment Outcome | 2022 |
Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Hospitalization; Humans | 2023 |
Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Catheter Ablation; Double-Blind Method; Dronedarone; Female; Heart Rate; Hospitalization; Humans; Male; Middle Aged; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substitution; Female; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Treatment Outcome | 2020 |
Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Female; Heart Rate; Humans; Male; Recurrence; Treatment Outcome | 2020 |
Efficacy and safety of dronedarone across age and sex subgroups: a post hoc analysis of the ATHENA study among patients with non-permanent atrial fibrillation/flutter.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Female; Humans; Infant, Newborn; Male | 2022 |
Cost-effectiveness of dronedarone in patients with atrial fibrillation in the ATHENA trial.
Topics: Aged; Amiodarone; Atrial Fibrillation; Cost-Benefit Analysis; Dronedarone; Drug Costs; Female; Follow-Up Studies; Humans; Male; Ontario; Quebec; Retrospective Studies | 2013 |
Efficacy of dronedarone versus propafenone in the maintenance of sinus rhythm in patients with atrial fibrillation after electrical cardioversion.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; Dronedarone; Electric Countershock; Female; Follow-Up Studies; Heart Rate; Humans; Male; Middle Aged; Propafenone; Recurrence; Time Factors | 2014 |
Interaction between digoxin and dronedarone in the PALLAS trial.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiotonic Agents; Cause of Death; Digoxin; Double-Blind Method; Dronedarone; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Electrocardiography; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome | 2014 |
A placebo-controlled, double-blind, randomized, multicenter study to assess the effects of dronedarone 400 mg twice daily for 12 weeks on atrial fibrillation burden in subjects with permanent pacemakers.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Dronedarone; Drug Administration Schedule; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Monitoring, Physiologic; Pacemaker, Artificial; Reference Values; Risk Assessment; Time Factors; Treatment Outcome | 2015 |
One-year safety and quality of life outcomes in patients with atrial fibrillation on dronedarone: prospective, non-interventional study in German ambulatory care.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Humans; Longitudinal Studies; Male; Middle Aged; Patient Safety; Patient Satisfaction; Prevalence; Prospective Studies; Quality of Life; Risk Assessment; Treatment Outcome | 2015 |
The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Pacemaker, Artificial; Ranolazine; Sodium Channel Blockers; Treatment Outcome | 2015 |
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Atrial Fibrillation; Circadian Rhythm; Double-Blind Method; Dronedarone; Exercise; Female; Heart Rate; Humans; Internationality; Male; Middle Aged; Physical Endurance; Time Factors; Treatment Outcome; Ventricular Function | 2008 |
[Efficacy of dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. Results of the EURIDIS and ADONIS].
Topics: Adult; Amiodarone; Atrial Fibrillation; Atrial Flutter; Dose-Response Relationship, Drug; Dronedarone; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Male; Middle Aged; Stroke Volume; Time Factors; Treatment Outcome | 2008 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; Creatinine; Double-Blind Method; Dronedarone; Female; Follow-Up Studies; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Risk Factors; Secondary Prevention; Treatment Outcome | 2009 |
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Electrocardiography; Endpoint Determination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nervous System Diseases; Risk Assessment; Thyroid Diseases | 2010 |
Dronedarone in patients with congestive heart failure: insights from ATHENA.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Creatinine; Dronedarone; Female; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Treatment Outcome; Ventricular Dysfunction, Left | 2010 |
Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies.
Topics: Aged; Amiodarone; Atrial Fibrillation; Dronedarone; Female; Hospitalization; Humans; Male; Middle Aged; Treatment Outcome | 2011 |
Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cause of Death; Combined Modality Therapy; Double-Blind Method; Dronedarone; Electric Countershock; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Risk; Secondary Prevention; Signal Processing, Computer-Assisted; Stroke; Utilization Review | 2011 |
Post-ATHENA and beyond.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Heart Failure; Heart Ventricles; Hospitalization; Humans; Risk Assessment; Secondary Prevention; Treatment Outcome | 2011 |
Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Critical Care; Dronedarone; Female; Follow-Up Studies; Hospitalization; Humans; Incidence; Kaplan-Meier Estimate; Length of Stay; Male; Secondary Prevention | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiovascular Diseases; Chronic Disease; Digoxin; Double-Blind Method; Dronedarone; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Risk Factors; Stroke | 2011 |
Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Diagnostic Tests, Routine; Dronedarone; Drug Costs; Europe; Female; Hospital Costs; Hospitalization; Humans; Male; Models, Economic; Office Visits; Quality-Adjusted Life Years; Stroke; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Electrocardiography; Female; Heart Rate; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Secondary Prevention; Time Factors | 2007 |
Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atria
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; Dronedarone; Hospitalization; Humans; Internationality; Placebo Effect; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2008 |
167 other study(ies) available for dronedarone and Auricular Fibrillation
| Article | Year |
|---|---|
Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I).
Topics: Administration, Intravenous; Animals; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Discovery; HEK293 Cells; Humans; Kv1.5 Potassium Channel; Mice; Molecular Structure; Piperazines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2014 |
Physician Network Connections Associated With Faster De-Adoption of Dronedarone for Permanent Atrial Fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Medicare; Physicians; United States | 2021 |
Risk of Major Bleeding in Patients With Atrial Fibrillation Taking Dronedarone in Combination With a Direct Acting Oral Anticoagulant (From a U.S. Claims Database).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Databases, Factual; Dronedarone; Drug Interactions; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Risk Assessment; Severity of Illness Index; United States; Young Adult | 2021 |
International cohort study on the effectiveness of dronedarone and other antiarrhythmic drugs for atrial fibrillation in real-world practice (EFFECT-AF).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; Humans; Male | 2022 |
[The Chinese expert recommendations on the clinical use of dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; China; Dronedarone; Humans | 2021 |
Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies.
Topics: Adonis; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Female; Humans; Pharmaceutical Preparations | 2022 |
Comparison of co-administration of amiodarone and rivaroxaban to co-administration of dronedarone and rivaroxaban for hemorrhage risks after atrial fibrillation ablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Hemorrhage; Humans; Rivaroxaban | 2022 |
Comparative Safety and Effectiveness of Sotalol Versus Dronedarone After Catheter Ablation for Atrial Fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Humans; Retrospective Studies; Sotalol | 2022 |
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Atrial Flutter; Dronedarone; Female; Heart Failure; Humans; Male; Middle Aged; Prognosis; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2022 |
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure and preserved or mildly reduced ejection fraction: closer to Ithaca after a long odyssey?
Topics: Atrial Fibrillation; Dronedarone; Heart Failure; Humans; Stroke Volume | 2022 |
Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Cytochrome P-450 CYP3A; Dronedarone; Drug Interactions; Hemorrhage; Humans; Pyrazoles; Pyridones; Rivaroxaban | 2022 |
Efficacy and Safety of Sustained-Release Metoprolol With Dronedarone After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation: A Propensity Matched Analysis.
Topics: Atrial Fibrillation; Catheter Ablation; Delayed-Action Preparations; Dronedarone; Humans; Metoprolol; Quality of Life; Recurrence; Retrospective Studies; Treatment Outcome | 2022 |
Novel methodology for the evaluation of symptoms reported by patients with newly diagnosed atrial fibrillation: Application of natural language processing to electronic medical records data.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Dizziness; Dronedarone; Dyspnea; Electronic Health Records; Humans; Natural Language Processing; Retrospective Studies; Sotalol; Syncope | 2023 |
A value-based budget impact model for dronedarone compared with other rhythm control strategies.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Sotalol | 2023 |
Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dronedarone; Humans; Ischemic Stroke; Propafenone; Stroke | 2023 |
Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Sotalol; Stroke Volume; Ventricular Function, Left; Veterans | 2023 |
Chapter 3: Evidence for the Use of Early Rhythm Control to Prevent Atrial Fibrillation Progression.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Hospitalization; Humans; Risk Factors | 2023 |
Chapter 2: Rate Versus Rhythm Control.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Heart Failure; Heart Rate; Hospitalization; Humans | 2023 |
Do amiodarone and dronedarone prevent thrombo-embolic stroke by treating the atrial myopathy of patients with atrial fibrillation? A provocative hypothesis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Embolic Stroke; Humans; Muscular Diseases | 2020 |
[Increased Ventricular Pacing Threshold Caused by Intake of Dronedaron].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Dronedarone; Heart; Humans; Pacemaker, Artificial; Sick Sinus Syndrome | 2020 |
Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Clinical Trials, Phase III as Topic; Dronedarone; Electric Countershock; Europe; Female; Heart Rate; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Recurrence; Retreatment; Risk Assessment; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome; United States | 2020 |
Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Databases, Factual; Diabetes Mellitus, Type 2; Dronedarone; Evidence-Based Medicine; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Medicare; Practice Patterns, Physicians'; Treatment Outcome; United States | 2020 |
Inhibitory Effects of Dronedarone on Small Conductance Calcium Activated Potassium Channels in Patients with Chronic Atrial Fibrillation: Comparison to Amiodarone.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium; Dronedarone; Female; Heart Atria; HEK293 Cells; Humans; Male; Middle Aged; Myocytes, Cardiac; Potassium Channels; Small-Conductance Calcium-Activated Potassium Channels | 2020 |
Case Report: Presumed Optic Neuropathy after Amiodarone and then Dronedarone for Treatment of Atrial Fibrillation.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Substitution; Humans; Male; Optic Nerve Diseases; Vision Disorders; Visual Acuity; Visual Fields | 2020 |
Outcomes Associated with Dronedarone Use in Patients with Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiovascular Diseases; Cohort Studies; Dronedarone; Epidemiologic Studies; Female; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; Risk Assessment; Treatment Outcome | 2020 |
Comparative clinical outcomes of dronedarone and sotalol in Asian patients with atrial fibrillation: a nationwide cohort study.
Topics: Aged; Anti-Arrhythmia Agents; Asian People; Atrial Fibrillation; Atrial Flutter; Cause of Death; Dronedarone; Female; Hospitalization; Humans; Male; Middle Aged; Patients; Retrospective Studies; Sotalol | 2020 |
Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Dronedarone; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Propafenone; Retrospective Studies; Rivaroxaban; Taiwan | 2021 |
An exploratory analysis of effects of poyendarone, a deuterated analogue of dronedarone, on the canine model of paroxysmal atrial fibrillation.
Topics: Administration, Intravenous; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Deuterium; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Dronedarone; Electrocardiography; Female; Heart Rate | 2021 |
Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Lung Diseases, Interstitial; Retrospective Studies; United States | 2021 |
Atrial resting membrane potential confers sodium current sensitivity to propafenone, flecainide and dronedarone.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dronedarone; Female; Flecainide; Heart Atria; Male; Membrane Potentials; Mice; Propafenone; Sodium; Voltage-Gated Sodium Channel Blockers | 2021 |
Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzofurans; Cell Line; Dronedarone; Drug Interactions; HEK293 Cells; Humans; Organic Anion Transporters, Sodium-Independent; Rivaroxaban | 2021 |
Evaluating the Risk of Digitalis Intoxication Associated With Concomitant Use of Dronedarone and Digoxin Using Real-World Data.
Topics: Adult; Atrial Fibrillation; Atrial Flutter; Digitalis; Digoxin; Dronedarone; Humans | 2021 |
Treatment of Postoperative New Onset Atrial Fibrillation with Repolarization Delaying Agents after Heart Surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Surgical Procedures; Dronedarone; Humans; Treatment Outcome | 2021 |
Dronedarone attenuates the duration of atrial fibrillation in a dog model of sustained atrial fibrillation.
Topics: Action Potentials; Administration, Oral; Amiodarone; Animals; Atrial Fibrillation; Disease Models, Animal; Dogs; Dronedarone; Heart Atria; Humans; Refractory Period, Electrophysiological; Time Factors | 2017 |
Effectiveness of Drugs in Routine Care: A Model for Sequential Monitoring of New Medicines Using Dronedarone as Example.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Computer Systems; Databases, Factual; Dronedarone; Drug Approval; Drug Monitoring; Electronic Health Records; Female; Flecainide; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Propensity Score; Sweden; Treatment Outcome | 2018 |
In vivo Analysis of the Anti-atrial Fibrillatory, Proarrhythmic and Cardiodepressive Profiles of Dronedarone as a Guide for Safety Pharmacological Evaluation of Antiarrhythmic Drugs.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Output; Disease Models, Animal; Dogs; Dronedarone; Electrocardiography; Heart Conduction System; Heart Rate; Male; Refractory Period, Electrophysiological; Risk Assessment; Time Factors; Torsades de Pointes; Ventricular Function, Left; Ventricular Pressure | 2018 |
Dronedarone produces early regression of myocardial remodelling in structural heart disease.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrial Remodeling; Dronedarone; Heart Diseases; Humans; Hypertension; Hypertrophy, Left Ventricular; Positron Emission Tomography Computed Tomography; Rats; Rats, Inbred SHR | 2017 |
Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other Antiarrhythmics.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Databases, Factual; Dronedarone; Female; Flecainide; Humans; Male; Middle Aged; Peripheral Nervous System Diseases; Propafenone; Retrospective Studies; Sotalol | 2018 |
Safety of apixaban in combination with dronedarone in patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dronedarone; Drug Interactions; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Registries; Retrospective Studies; Risk Assessment; Stroke; Sweden; Warfarin | 2018 |
Re-gaining confidence in contemporary dronedarone use.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone | 2018 |
Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Dronedarone; Female; Flecainide; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Sotalol; Survival Rate; Sweden; Tachycardia, Ventricular | 2018 |
Impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation patients followed in general practices in Germany.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Databases, Factual; Dronedarone; Female; Follow-Up Studies; General Practice; Germany; Humans; Male; Middle Aged; Myocardial Infarction; Stroke | 2019 |
Efficacy and safety of dronedarone in patients with amiodarone-induced hyperthyroidism: a clinical study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Hyperthyroidism; Male; Middle Aged; Prospective Studies | 2018 |
Apples will never be oranges, but when you go fishing you may get a bite.
Topics: Atrial Fibrillation; Citrus sinensis; Dronedarone; General Practice; Germany; Humans; Malus; Myocardial Infarction; Stroke | 2019 |
Observational study of dronedarone in Taiwanese patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Logistic Models; Male; Middle Aged; Prospective Studies; Quality of Life; Severity of Illness Index; Taiwan; Treatment Outcome | 2020 |
Current practice of antiarrhythmic drug therapy for prevention of atrial fibrillation in Europe: The European Heart Rhythm Association survey.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Dronedarone; Electrocardiography; Europe; Guideline Adherence; Health Care Surveys; Humans; Patient Selection; Practice Guidelines as Topic; Practice Patterns, Physicians'; Predictive Value of Tests; Recurrence; Treatment Outcome | 2013 |
Dronedarone for the treatment of non-permanent atrial fibrillation: National Institute for Health and Clinical Excellence guidance.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Drug Approval; Humans; National Institutes of Health (U.S.); Practice Guidelines as Topic; United States | 2013 |
Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.
Topics: Acetanilides; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dronedarone; Drug Therapy, Combination; Female; Piperazines; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Sotalol | 2013 |
Which patient is most likely to benefit from dronedarone? Analysis from the Magdeburg Dronedarone Registry (MADRE study).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Heart Atria; Humans; Male; Middle Aged; Organ Size; Recurrence; Registries | 2013 |
The dronedarone shared-care clinical model and database: a coordinated paradigm to optimize management of evolving clinical recommendations.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Dronedarone; Female; Guideline Adherence; Humans; Liver Function Tests; Male; Middle Aged; Northern Ireland; Practice Guidelines as Topic; Product Surveillance, Postmarketing; Registries | 2013 |
Severe toxic hepatitis associated with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical and Drug Induced Liver Injury, Chronic; Dronedarone; Female; Humans; Severity of Illness Index | 2013 |
Ventricular ectopy and QTc-interval prolongation associated with dronedarone therapy.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography, Ambulatory; Fatigue; Humans; Long QT Syndrome; Male; Ventricular Premature Complexes | 2013 |
Inhibition of I(f) in the atrioventricular node as a mechanism for dronedarone's reduction in ventricular rate during atrial fibrillation.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrioventricular Node; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Disease Models, Animal; Dronedarone; Drug Therapy, Combination; Electrocardiography; Heart Rate; Heart Ventricles; Ivabradine; Male; Swine; Ventricular Function, Left | 2013 |
The funny and not-so-funny effects of dronedarone.
Topics: Amiodarone; Animals; Atrial Fibrillation; Atrioventricular Node; Dronedarone; Electrocardiography; Heart Rate; Heart Ventricles; Male; Ventricular Function, Left | 2013 |
Dronaderone-induced phototoxicity.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dermatitis, Phototoxic; Dronedarone; Drug Eruptions; Female; Humans; Middle Aged | 2013 |
Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; Dronedarone; Heart Conduction System; Heart Rate; Hospitalization; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
[Appropriateness criteria for the treatment of atrial fibrillation with dronedarone: practical issues. An Italian cardiologists' expert opinion].
Topics: Amiodarone; Atrial Fibrillation; Dronedarone; Humans; Practice Guidelines as Topic | 2013 |
Non-standard dose dronedarone in treating atrial fibrillation patients.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Female; Humans; Male; Retrospective Studies; Treatment Outcome | 2014 |
Efficacy and tolerability of dronedarone for patients with atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Surgical Procedures; Catheter Ablation; Dronedarone; Drug Administration Schedule; Electrocardiography; Female; Heart Rate; Humans; Male; Middle Aged; Time Factors; Treatment Outcome | 2013 |
Dronedarone: an alternate choice to sotalol and amiodarone in the treatment of atrial fibrillation/flutter in patients who have coronary heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Disease; Dronedarone; Heart Conduction System; Heart Rate; Humans; Male | 2014 |
Assessment of dronedarone utilization using US claims databases.
Topics: Adult; Aged; Amiodarone; Atrial Fibrillation; Contraindications; Creatinine; Databases, Factual; Dronedarone; Drug Interactions; Drug Prescriptions; Drug Utilization Review; Female; Heart Failure; Hospitalization; Humans; Insurance Claim Review; Middle Aged; Retrospective Studies; Young Adult | 2014 |
Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Dronedarone; Evidence-Based Medicine; Heart Rate; Humans; Practice Guidelines as Topic; Recurrence; Reproducibility of Results; United States | 2014 |
Impact of dronedarone treatment on healthcare resource utilization in patients with atrial fibrillation/flutter.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cohort Studies; Dronedarone; Emergency Service, Hospital; Female; Health Resources; Health Services; Hospitalization; Humans; Male; Middle Aged; Retrospective Studies; United States; Young Adult | 2014 |
Safety of dronedarone in routine clinical care.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Heart Failure; Humans; Liver Failure; Male | 2014 |
Dronedarone: "real-world" data vis-à-vis data from randomized clinical trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Male | 2014 |
Evaluation of dronedarone as a therapeutic option for patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Hospitalization; Humans; Incidence; Randomized Controlled Trials as Topic; Secondary Prevention | 2014 |
Editorial: advances in the therapy of atrial fibrillation: incrementally progressive but not without missteps.
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dronedarone; Drug Design; Humans; Pyrrolidines | 2014 |
Are we at the goal line with the novel oral anticoagulants and have we reached the end of the line for dronedarone and vernakalant--or is there more to come?
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Dronedarone; Embolism; Humans; Pyrrolidines; Stroke | 2014 |
In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology.
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Computer Simulation; Dose-Response Relationship, Drug; Dronedarone; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Heart Atria; Heart Rate; Humans; Models, Cardiovascular; Mutation; Numerical Analysis, Computer-Assisted; Recurrence; Time Factors; Treatment Outcome | 2014 |
Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Female; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Sotalol | 2014 |
Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Databases, Factual; Dronedarone; Drug Substitution; Female; Flecainide; Humans; Logistic Models; Longitudinal Studies; Male; Middle Aged; Propafenone; Sotalol | 2015 |
Toxic Epidermal Necrolysis During Dronedarone Treatment: First Report of a Severe Serious Adverse Event Of A New Antiarrhythmic Drug.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Dronedarone; Fatal Outcome; Female; Heart Rate; Humans; Multiple Organ Failure; Severity of Illness Index; Stevens-Johnson Syndrome; Time Factors | 2015 |
Effects of dronedarone on ventricular repolarization and repolarization dynamics in patients with preserved left ventricular systolic function.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Male; Middle Aged; Systole; Ventricular Function, Left | 2015 |
Concomitant use of dronedarone with dabigatran in patients with atrial fibrillation in clinical practice.
Topics: Aged; Amiodarone; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Dronedarone; Female; Glomerular Filtration Rate; Healthy Volunteers; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Registries; Time Factors; Treatment Outcome | 2015 |
Diffuse alveolar damage in a patient receiving dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Diagnosis, Differential; Dronedarone; Female; Humans; Lung Diseases, Interstitial; Pulmonary Alveoli; Tomography, X-Ray Computed | 2015 |
Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; Humans; Male; Patient Admission; Pennsylvania; Phenethylamines; Recurrence; Retrospective Studies; Sotalol; Stroke; Sulfonamides | 2016 |
The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Prescriptions; Drug Utilization; England; Flecainide; Humans; Retrospective Studies; Sotalol | 2016 |
Rise and fall of dronedarone: the need for new drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone | 2016 |
Concomitant Rivaroxaban and Dronedarone Administration in Patients With Nonvalvular Atrial Fibrillation.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Rivaroxaban; Stroke; Treatment Outcome | 2017 |
New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Dronedarone; Humans; Pyrrolidines | 2008 |
Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiotonic Agents; Clinical Trials as Topic; Dronedarone; Heart Failure; Humans | 2008 |
[Current pharmacological management of atrial fibrillation management by practice cardiologists - news from congress in Munich].
Topics: Amiodarone; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Cardiology; Congresses as Topic; Dronedarone; Europe; Humans; Practice Guidelines as Topic; Secondary Prevention | 2008 |
Alternatives to amiodarone: search for the Holy Grail.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzofurans; Combined Modality Therapy; Dose-Response Relationship, Drug; Dronedarone; Humans; Pacemaker, Artificial; Phenethylamines; Sulfonamides | 2009 |
Trial watch: novel antiarrhythmic agent shows promise in Phase III trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dronedarone; Humans | 2009 |
Dronedarone for atrial fibrillation--an odyssey.
Topics: Advisory Committees; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Dronedarone; Drug Approval; Humans; Molecular Structure; Stroke Volume; United States; United States Food and Drug Administration | 2009 |
New pharmacological options for patients with atrial fibrillation: the ATHENA trial.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Endpoint Determination; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Hospitalization; Humans | 2009 |
Dronedarone in atrial fibrillation.
Topics: Acute Coronary Syndrome; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Dronedarone; Heart Rate; Hospitalization; Humans | 2009 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Dronedarone; Hospitalization; Humans; Secondary Prevention | 2009 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Hospitalization; Humans; Male; Secondary Prevention; Sex Factors | 2009 |
Amiodarone or dronedarone for atrial fibrillation: too early to know the winner?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Heart Rate; Humans; Treatment Outcome | 2009 |
Rethinking the reasons to treat atrial fibrillation? The role of dronedarone in reducing cardiovascular hospitalizations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Hospitalization; Humans; Risk Factors | 2009 |
Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Female; Humans; International Normalized Ratio; Male; Middle Aged; Multivariate Analysis; Placebos; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2009 |
Dronedarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Randomized Controlled Trials as Topic | 2009 |
Dronedarone (Multaq) for atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Drug Interactions; Humans; United States; United States Food and Drug Administration | 2009 |
Atrial fibrillation: Dronedarone and amiodarone-the safety versus efficacy debate.
Topics: Algorithms; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug-Related Side Effects and Adverse Reactions; Humans | 2010 |
Atrial fibrillation. DIONYSOS study comparing dronedarone with amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic | 2010 |
[Comparison of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. Indirect meta-analysis].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Meta-Analysis as Topic; Treatment Outcome | 2010 |
FDA drug information that never reaches clinicians.
Topics: Advisory Committees; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Approval; Drug Labeling; Humans; Information Dissemination; United States; United States Food and Drug Administration | 2010 |
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bias; Dronedarone; Electrocardiography; Humans; Meta-Analysis as Topic; Odds Ratio; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome | 2010 |
Dronedarone is superior to placebo the case for optimism.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Bias; Dronedarone; Electrocardiography; Humans; Odds Ratio; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
A perspective on DIONYSOS.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Randomized Controlled Trials as Topic | 2010 |
Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiovascular Diseases; Clinical Trials as Topic; Dronedarone; Humans | 2010 |
Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Biological Availability; Cytochrome P-450 CYP3A; Dronedarone; Drug Interactions; Food-Drug Interactions; Half-Life; Humans | 2010 |
Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Dronedarone; Electrophysiologic Techniques, Cardiac; Heart Atria; Heart Conduction System; Treatment Outcome | 2010 |
Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Controlled Clinical Trials as Topic; Cost Savings; Databases as Topic; Dronedarone; Drug Costs; Female; Hospital Costs; Hospital Mortality; Hospitalization; Humans; Inpatients; Male; Medicare Part B; Models, Economic; Retrospective Studies; Time Factors; Treatment Outcome; United States | 2010 |
Dronedarone: a review of characteristics and clinical data.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Interactions; Humans | 2010 |
Amiodarone and dronedarone: the worker bee and the drone?
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dose-Response Relationship, Drug; Dronedarone; Electrophysiologic Techniques, Cardiac; Heart Atria; Heart Conduction System; Humans; Treatment Outcome | 2010 |
Worsening heart failure in the setting of dronedarone initiation.
Topics: Acute Kidney Injury; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Progression; Dronedarone; Heart Failure; Humans; Liver Failure, Acute; Male; Middle Aged | 2010 |
Dronedarone: where does it fit in the treatment of atrial fibrillation?
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Drug Therapy, Combination; Humans; Secondary Prevention; Treatment Outcome | 2010 |
Role of dronedarone in atrial fibrillation: more questions than answers.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Humans | 2010 |
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.
Topics: Acetanilides; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Dronedarone; Drug Synergism; Drug Therapy, Combination; Piperazines; Ranolazine | 2010 |
Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Treatment Outcome | 2010 |
Dronedarone. atrial fibrillation: too many questions about long-term adverse effects.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; European Union; Heart Failure; Heart Rate; Humans | 2010 |
The dronedarone odyssey.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Drug Approval; Europe; Humans; United States | 2010 |
[Advances in the prevention of cerebral ischaemia due to atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Dabigatran; Diagnosis, Differential; Dronedarone; Humans; Vitamin K | 2010 |
A patient with recurrent atrial fibrillation and monomorphic ventricular tachycardia treated successfully with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibrillators, Implantable; Dronedarone; Humans; Male; Secondary Prevention; Tachycardia, Ventricular; Treatment Outcome | 2011 |
Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Randomized Controlled Trials as Topic | 2010 |
[New antiarrhythmic drugs for treatment of atrial fibrillation].
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Design; Electric Countershock; Humans; Membrane Transport Modulators; Pyrrolidines | 2010 |
Treatment of atrial fibrillation in 2010 and beyond.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Prevalence; Quality of Life; United States | 2010 |
Augmenting maintenance of sinus rhythm in the control of atrial fibrillation by antiarrhythmic drug combinations.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Drug Therapy, Combination; Humans; Sotalol | 2010 |
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Topics: Algorithms; Amiodarone; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Combined Modality Therapy; Dronedarone; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Recurrence; Treatment Outcome | 2011 |
Mixed treatment comparisons for atrial fibrillation: evidence network or bewildering entanglement?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Evidence-Based Medicine; Flecainide; Humans; Propafenone; Sotalol; Treatment Outcome | 2011 |
Dronedarone for atrial fibrillation: How does it compare with amiodarone?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug Interactions; Humans; Prescription Fees | 2011 |
What's new in...atrial fibrillation. Is dronedarone more effective than amiodarone?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2011 |
[Treatment of atrial fibrillation: when to use drugs or to perform ablation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Clinical Trials as Topic; Dronedarone; Follow-Up Studies; Humans; Male; Middle Aged; Postoperative Complications; Recurrence; Time Factors; Treatment Outcome | 2010 |
The impact of dronedarone on lone atrial fibrillation: perhaps not such a "benign" arrhythmia?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Male | 2011 |
Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Heart Rate; Humans; Stroke | 2011 |
[Perspectives and recommendations for the anti-arrhythmic treatment of atrial fibrillation: focus on dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Practice Guidelines as Topic; Randomized Controlled Trials as Topic | 2011 |
Hospitalization: a relevant endpoint in atrial fibrillation management?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Hospitalization; Humans; Male | 2011 |
Severe docetaxel overdose induced by pharmacokinetic interaction with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Atrial Fibrillation; Docetaxel; Dronedarone; Drug Administration Schedule; Drug Overdose; Fatal Outcome; Humans; Male; Mucositis; Prostatic Neoplasms; Taxoids | 2011 |
Atrial fibrillation: outpatient presentation and management.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Electrocardiography; Heart Rate; Humans; Male; Outpatients; Stroke; Treatment Outcome | 2011 |
Acute liver failure associated with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Dronedarone; Female; Humans; Liver; Liver Failure, Acute; Liver Function Tests; Liver Transplantation; Treatment Outcome | 2011 |
Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Contraindications; Databases, Factual; Dronedarone; Drug Interactions; Drug Prescriptions; Drug Utilization Review; Female; Humans; Insurance Claim Review; Male; Middle Aged; United States; Young Adult | 2011 |
Dronedarone in atrial fibrillation--Jekyll and Hyde?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Female; Humans; Male | 2011 |
Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs.
Topics: Acute Coronary Syndrome; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Blotting, Western; Cardiac Pacing, Artificial; Cell Line; Coronary Circulation; Dronedarone; Gene Expression; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Microcirculation; Myocytes, Cardiac; NADPH Oxidases; Oxidative Stress; Phosphorylation; Protein Kinase C; Real-Time Polymerase Chain Reaction; Swine | 2012 |
Dronedarone: a new hope for stroke prevention in atrial fibrillation?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Risk Factors; Stroke | 2011 |
Dronedarone trial stopped due to excess mortality.
Topics: Amiodarone; Atrial Fibrillation; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Dronedarone; Early Termination of Clinical Trials; Humans | 2011 |
[Atrial fibrillation. PALLAS study: when dronedarone becomes a risk].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Contraindications; Dronedarone; Early Termination of Clinical Trials; Endpoint Determination; Humans; Patient Admission; Risk Factors; Survival Rate | 2011 |
Second chance for dronedarone after recent setback?
Topics: Acetanilides; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Contraindications; Dronedarone; Drug Approval; Drug Therapy, Combination; Electrocardiography; Europe; Humans; Piperazines; Ranolazine; Sodium Channel Blockers; Survival Analysis; United States | 2012 |
Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS.
Topics: Acute Coronary Syndrome; American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Fibrinolytic Agents; Humans; Lactones; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; United States; Venous Thromboembolism | 2012 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Finland; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
[The PALLAS study].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Confidence Intervals; Dronedarone; Humans; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2012 |
[Between guidelines and regulatory decisions: the odyssey of dronedarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug and Narcotic Control; Evidence-Based Medicine; Heart Rate; Humans; Liver Failure, Acute; Practice Guidelines as Topic; Risk Factors; Treatment Outcome | 2012 |
Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Cardiovascular Diseases; Cost-Benefit Analysis; Dronedarone; Europe; Health Status; Humans; Models, Economic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sex Factors; Survival Analysis | 2013 |
[Rhythm---control in atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Double-Blind Method; Dronedarone; Drug Approval; Early Termination of Clinical Trials; Electrocardiography; Germany; Humans; Randomized Controlled Trials as Topic; Survival Rate | 2012 |
Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study).
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cohort Studies; Dronedarone; Female; Follow-Up Studies; Gastrointestinal Diseases; Germany; Humans; Male; Middle Aged; Prospective Studies; Registries; Treatment Outcome | 2013 |
Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.
Topics: Amiodarone; Animals; Atrial Fibrillation; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Dronedarone; Ion Channel Gating; Membrane Potentials; Myocardium; Oocytes; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Tandem Pore Domain; Transfection; Xenopus laevis | 2012 |
A 73-year-old man with interstitial lung disease due to dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Lung; Lung Diseases, Interstitial; Male | 2012 |
Possible proarrhythmia with dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Humans; Male; Middle Aged; Tachycardia, Ventricular; Treatment Outcome | 2013 |
Stable cystatin C serum levels confirm normal renal function in patients with dronedarone-associated increase in serum creatinine.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biomarkers; Creatinine; Cystatin C; Dronedarone; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Protein Stability; Reproducibility of Results; Up-Regulation | 2013 |
Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia.
Topics: Acetanilides; Amiodarone; Animals; Atrial Fibrillation; Chromatography, High Pressure Liquid; Disease Models, Animal; Dronedarone; Drug Therapy, Combination; Electrocardiography; Hemodynamics; Piperazines; Ranolazine; Swine; Tachycardia, Ventricular | 2013 |
[Update 2012: new European guidelines for atrial fibrillation].
Topics: Amiodarone; Anticoagulants; Atrial Fibrillation; Dronedarone; Germany; Humans; Long-Term Care; Practice Guidelines as Topic; Risk Assessment; Stroke; Thromboembolism; Vitamin K | 2012 |
[New antiarrhythmic drugs for the treatment of atrial fibrillation].
Topics: Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Pyrrolidines | 2012 |
Dronedarone: is it time to turn it down?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Dronedarone; Humans; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
Effects of dronedarone and amiodarone on atrial fibrillatory rate in patients with persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Electrocardiography; Female; Humans; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2013 |
[Febrile maculopapular eruption due to dronedarone].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Biopsy; Diagnosis, Differential; Dronedarone; Drug Eruptions; Fever; Humans; Male; Skin | 2012 |
Effects of dronedarone started rapidly after amiodarone discontinuation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Dronedarone; Drug Substitution; Female; Half-Life; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Patient Selection; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Treatment Outcome | 2013 |
This DAFNE is definitely not that DAFNE.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Electric Countershock; Humans; Terminology as Topic | 2005 |
Dronedarone: a new antiarrhythmic agent.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Biological Availability; Clinical Trials as Topic; Dronedarone; Humans; Metabolic Clearance Rate; Treatment Outcome | 2006 |
[Dronedarone establishes and maintains control of sinus rhythm].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans | 2006 |
Comment on dronedarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Humans; Outcome Assessment, Health Care; Patient Selection; Treatment Outcome | 2006 |
Maintaining sinus rhythm--making treatment better than the disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Dronedarone; Heart Failure; Humans; Secondary Prevention | 2007 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Humans; Hyperthyroidism; Proportional Hazards Models; Secondary Prevention | 2007 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Heart Rate; Humans; Quality of Life; Secondary Prevention | 2007 |
Is dronedarone effective for the prevention of recurrent atrial fibrillation?
Topics: Amiodarone; Atrial Fibrillation; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Dronedarone; Drug Administration Schedule; Electrocardiography; Female; Humans; Male; Multicenter Studies as Topic; Probability; Prognosis; Randomized Controlled Trials as Topic; Secondary Prevention; Sensitivity and Specificity; Severity of Illness Index; Survival Rate; Treatment Outcome | 2008 |
Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cell Separation; Dronedarone; Guanosine 5'-O-(3-Thiotriphosphate); Guinea Pigs; Heart Atria; In Vitro Techniques; Myocardium; Patch-Clamp Techniques; Potassium Channels; Receptors, Muscarinic; Stimulation, Chemical | 2000 |